Islex Therapeutics is dedicated to developing precision therapies for diabetes with severe beta cell loss in the pancreatic islets—the exclusive site of insulin production in the body. Islex Therapeutics is a pioneer in developing the world's only platform for targeted beta cell therapies. This groundbreaking biotechnology is rooted in the discovery of an islet-specific cell-surface autoantigen, ZnT8. By harnessing the natural islet-homing ability of a ZnT8 autoantibody, Islex Therapeutics re-engineers it to precisely guide antibody-conjugated therapeutics to islets, thereby enhancing drug efficacy at the disease site while minimizing off-target toxicity. Presently, the company is focused on the preclinical development of a therapeutic antibody that can prevent and reverse autoimmune diabetes in mice. Concurrently, Islex Therapeutics is advancing next-generation immunoregulatory and regenerative therapeutics to establish a pipeline of islet-targeted combination therapies.